Key Points
- Insider sale: Director Scott Davies sold 323 shares on Dec. 12 at an average price of $136.09 for $43,957.07, trimming his holdings by 1.77% to 17,887 shares valued at about $2.43M.
- Recent results and guidance: Illumina reported $1.34 EPS on $1.08B revenue (both above consensus) and set FY2025 guidance of $4.650–$4.750 EPS, compared with a sell-side average expected EPS of ~4.51 for the year.
- Valuation and analyst view: The company has a $20.1B market cap and P/E of 29.5, a 1-year range of $68.70–$153.06, and an average analyst rating of "Hold" with a $117.19 average target price.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) insider Scott Davies sold 323 shares of the company's stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares of the company's stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Illumina Stock Performance
NASDAQ:ILMN opened at $131.56 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The firm has a market cap of $20.10 billion, a price-to-earnings ratio of 29.50, a price-to-earnings-growth ratio of 2.41 and a beta of 1.44. The firm's fifty day moving average price is $116.09 and its 200 day moving average price is $103.59. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $153.06.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts' consensus estimates of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the firm earned $1.14 EPS. Illumina's quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.
Institutional Trading of Illumina
Several large investors have recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its position in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company's stock valued at $28,000 after buying an additional 115 shares in the last quarter. Quent Capital LLC acquired a new stake in Illumina in the 3rd quarter valued at about $29,000. Quarry LP purchased a new position in Illumina during the 3rd quarter valued at about $32,000. Aster Capital Management DIFC Ltd acquired a new position in Illumina during the third quarter worth about $33,000. Finally, Rise Advisors LLC lifted its holdings in shares of Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 224 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on ILMN shares. TD Cowen lifted their price objective on Illumina from $110.00 to $115.00 and gave the company a "hold" rating in a report on Friday, October 31st. Cowen restated a "hold" rating on shares of Illumina in a research note on Friday, October 31st. Barclays upped their price objective on Illumina from $100.00 to $110.00 and gave the stock an "underweight" rating in a report on Monday. Evercore ISI raised their target price on Illumina from $132.00 to $142.00 and gave the company an "outperform" rating in a report on Friday, October 31st. Finally, Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a research note on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Illumina has an average rating of "Hold" and an average target price of $117.19.
Read Our Latest Stock Report on Illumina
Illumina Company Profile
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
